Hypoxia-inducible factor-1α polymorphisms are associated with genetic aberrations in lung cancer

Respirology

Volumn 16, Issue 5, 2011, Pages 796-802

  Putra, Andika C ^a   Tanimoto, Keiji ^a   Arifin, Marina ^a   Hiyama, Keiko ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Carcinogenesis; Genomic instability; Hypoxia inducible factor 1; Lung cancer; Polymorphism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P16; PROTEIN P53;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DNA REPAIR; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE INACTIVATION; GENE REPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOMIC INSTABILITY; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADENOCARCINOMA; AGED; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; GENOTYPE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; SMALL CELL LUNG CARCINOMA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959892977     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.01972.x     Document Type: Article

References (36)

1. Miller YE. Pathogenesis of lung cancer: 100 year report. Am. J. Respir. Cell Mol. Biol. 2005; 33: 216-23.
2. Sato M, Shames DS, Gazdar AF et al. A translational view of the molecular pathogenesis of lung cancer. J. Thorac. Oncol. 2007; 2: 327-43.
3. Sun S, Schiller JH, Spinola M et al. New molecularly targeted therapies for lung cancer. J. Clin. Invest. 2007; 117: 2740-50.
4. Bowman RV, Yang IA, Semmler AB et al. Epigenetics of lung cancer. Respirology 2006; 11: 355-65. (Pubitemid 43824331)
5. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J. Cell. Biochem. 2009; 107: 1053-62.
6. Brahimi-Horn MC, Pouyssegur J. HIF at a glance. J. Cell Sci. 2009; 122: 1055-7.
7. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J. Mol. Med. 2007; 85: 1301-7.
8. Bardos JI, Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochim. Biophys. Acta 2005; 1755: 107-20.
9. Schmid T, Zhou J, Brune B. HIF-1 and p53: communication of transcription factors under hypoxia. J. Cell. Mol. Med. 2004; 8: 423-31.
10. Koshiji M, To KK, Hammer S et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol. Cell. 2005; 17: 793-803.
11. Nakamura H, Tanimoto K, Hiyama K et al. Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2. Oncogene 2008; 27: 4200-9. (Pubitemid 351969910)
12. Chan N, Koch CJ, Bristow RG. Tumor hypoxia as a modifier of DNA strand break and cross-link repair. Curr. Mol. Med. 2009; 9: 401-10.
13. Huang LE, Bindra RS, Glazer PM et al. Hypoxia-induced genetic instability - a calculated mechanism underlying tumor progression. J. Mol. Med. 2007; 85: 139-48.
14. Meng AX, Jalali F, Cuddihy A et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother. Oncol. 2005; 76: 168-76.
15. Tanimoto K, Yoshiga K, Eguchi H et al. Hypoxia-inducible factor- 1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003; 24: 1779-83. (Pubitemid 37408141)
16. Ollerenshaw M, Page T, Hammonds J et al. Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet. Cytogenet. 2004; 153: 122-6.
17. Lee JY, Choi JY, Lee KM et al. Rare variant of hypoxia-inducible factor-1alpha (HIF-1A) and breast cancer risk in Korean women. Clin. Chim. Acta 2008; 389: 167-70.
18. Konac E, Onen HI, Metindir J et al. An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers. Cancer Detect. Prev. 2007; 31: 102-9.
19. Konac E, Dogan I, Onen HI et al. Genetic variations in the hypoxia-inducible factor-1alpha gene and lung cancer. Exp. Biol. Med. (Maywood) 2009; 234: 1109-16.
20. Mendoza C, Sato H, Hiyama K et al. Allelotype and loss of heterozygosity around the L-myc gene locus in primary lung cancers. Lung Cancer 2000; 28: 117-25. (Pubitemid 30136411)
21. Hiyama K, Ishioka S, Shirotani Y et al. Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and Rb. Oncogene 1995; 10: 937-44.
22. Arifin M, Hiyama K, Tanimoto K et al. EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung. Oncol. Rep. 2007; 17: 1405-11.
23. Arifin M, Tanimoto K, Putra AC et al. Carcinogenesis and cellular immortalization without persistent inactivation of p16/Rb pathway in lung cancer. Int. J. Oncol. 2010; 36: 1217-27.
24. Sobin L, Hermanek P, Hutter R. TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer 1988; 61: 2310-14.
25. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem. Pharmacol. 2000; 59: 47-53.
26. Koukourakis MI, Papazoglou D, Giatromanolaki A et al. C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF-1alpha gene define HIF-1alpha protein expression in non-small cell lung cancer. Lung Cancer 2006; 53: 257-62. (Pubitemid 44209281)
27. Lee CH, Lee MK, Kang CD et al. Differential expression of hypoxia inducible factor-1alpha and tumor cell proliferation between squamous cell carcinomas and adenocarcinomas among operable non-small cell lung carcinomas. J. Korean Med. Sci. 2003; 18: 196-203.
28. Sieber O, Heinimann K, Tomlinson I. Genomic stability and tumorigenesis. Semin. Cancer Biol. 2005; 15: 61-6.
29. Minna JD, Fong K, Zochbauer-Muller S et al. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J. 2002; 8(Suppl. 1): S41-6.
30. Osada H, Takahashi T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 2002; 21: 7421-34. (Pubitemid 35305598)
31. Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci. 2004; 95: 197-204. (Pubitemid 38489084)
32. Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem. Biophys. Res. Commun. 2005; 331: 868-80.
33. Mertens F, Johansson B, Hoglund M et al. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res. 1997; 57: 2765-80. (Pubitemid 27283792)
34. Giaretti W, Molinu S, Ceccarelli J et al. Chromosomal instability, aneuploidy, and gene mutations in human sporadic colorectal adenomas. Cell. Oncol. 2004; 26: 301-5.
35. Beckner ME, Sasatomi E, Swalsky PA et al. Loss of heterozygosity reveals non-VHL allelic loss in hemangioblastomas at 22q13. Hum. Pathol. 2004; 35: 1105-11.
36. Mihaylova VT, Bindra RS, Yuan J et al. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol. Cell Biol. 2003; 23: 3265-73.